Skip to main content
. 2019 Jan-Mar;15(1):32–38. doi: 10.14797/mdcj-15-1-32

Table 2.

Future therapies in development. ANGPTL3: angiopoietin-like 3; apo: apolipoprotein; Lp(a): lipoprotein(a); siRNA: small interfering RNA

AGENT MECHANISM OF ACTION PRIMARY LIPID COMPONENT TARGET
Inclisiran (ALN-PCSsc) siRNA to PCSK9 LDL-C
Bempedoic acid (ETC-1002) Inhibition of ATP citrate lyase LDL-C
AKCEA-APO(a)-LRX Antisense to apo(a) Lp(a)
AKCEA-APOCIII-LRX Antisense to apoCIII Triglycerides
Evinacumab Human monoclonal antibody to ANGPTL3 Triglycerides and cholesterol